| CEO Name | Makoto Inoue |
| Nationality | Japan |
| Net Worth Estimation | $10 million |
Makoto Inoue's estimated net worth of around $10 million USD is based on his executive compensation, stock holdings, and performance incentives as CEO of Otsuka Pharmaceutical Co., Ltd. His financial standing reflects the company's global revenue, market capitalization, and industry stature in pharmaceuticals and nutraceuticals.
Makoto Inoue, CEO of Otsuka Pharmaceutical Co., Ltd., has an estimated net worth of $10,000,000, which is 11.1% of the maximum CEO net worth and the minimum in the healthcare business category range ($10,000,000-$90,000,000). His net worth is at the lowest point within the estimated range for healthcare CEOs.
Business Category: Healthcare
Minimum Net Worth (estimation): 10000000 USD
Maximum Net Worth (estimation): 90000000 USD
Makoto Inoue Performance in Otsuka Pharmaceutical Co., Ltd.
Makoto Inoue, CEO of Otsuka Pharmaceutical Co., Ltd., demonstrates strategic leadership by driving innovation and global expansion in the pharmaceutical and nutraceutical sectors. His decision-making emphasizes sustainable growth, investment in R&D, and fostering collaborations to enhance product pipelines and market presence. Under Inoue's leadership, Otsuka has seen improved financial performance, strengthened competitive positioning, and increased influence in the global healthcare industry.
Latest News
Otsuka Pharmaceutical Enters Licensing Deal for Gene Therapy and CEO Insights on AI and Access
Otsuka Pharmaceutical recently secured exclusive Asia-Pacific rights to 4DMT's ophthalmic gene therapy candidate 4D-150, targeting retinal diseases, with a $420 million deal to fund phase 3 trials and commercialization. The North American CEO, Tarek Rabah, highlighted AI's potential to improve patient access and healthcare outcomes, especially in psychiatry and neurology sectors.
Source: http://www.otsuka.co.jp/en/company/newsreleases/2025/